JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.

Thumbnail
View / Open Files
Authors
  Gallipoli, Paolo
Publication Date
2018-12
Journal Title
Leuk Res
ISSN
0145-2126
Publisher
Elsevier BV
Volume
75
Pages
71-72
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item record
Citation
Gallipoli, P. (2018). JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.. Leuk Res, 75 71-72. https://doi.org/10.1016/j.leukres.2018.10.010
Keywords
Antineoplastic Agents, Humans, Janus Kinase 2, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Nitriles, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines
Sponsorship
Medical Research Council (MC_PC_12009)
Wellcome Trust (109967/Z/15/Z)
Identifiers
External DOI: https://doi.org/10.1016/j.leukres.2018.10.010
This record's URL: https://www.repository.cam.ac.uk/handle/1810/286785
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics



Total file downloads (since January 2020). For more information on metrics see the IRUS guide.